Patient Profile
ADA_2026Predictor Settings
Guideline Context
Select patient parameters to initiate the decision engine.
⚡
Awaiting Parameters
Complete the patient profile on the left to activate comparative drug intelligence and outcome modeling.
Primary Recommendation
Semaglutide 2.4mg
...
Pivotal Trial
SELECT Trial
Target Dose
2.4mg QW
Safety Guardrails
No active contraindications detected for this profile.
Therapeutic Fit Profile
5-Metric AnalysisHigher Area = Better Clinical Fit
Titration Outcome Predictor
Projected A1c/Weight RCT Path
RWE (Expected)
Standard Titration Protocol
FDA-Approved escalation to mitigate GI adverse events.
Est. Time to Target
16-20 Weeks
💡
Clinical Persistence Factor
Studies like SUSTAIN-RWE show that persistence is the primary driver of outcome success. Patients who bridge the first 12 weeks of GI symptoms achieve 85% of trial weight loss.